Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: A case report

Kijima, Toshiki; Fujii, Yasuhisa; Suyama, Taisuke; Okubo, Yuhei; Yonese, Junji; Fukui, Iwao

doi:10.1111/j.1442-2042.2008.02044.x

Cited by 8 publications

(4 citation statements)

References 9 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Indeed, the inhibitory effect of bisphosphonate on tumor growth is still inconsistent for soft tumors (33)(34)(35)). Even at the clinical level, few data have reported an antitumor effect of zoledronic acid against visceral metastases (36,37), and conflicting results have been highly discussed (38). In our ES models, it is clear that the doses of zoledronic acid that prevented tumor development in bone were unable to significantly influence soft tissue tumor growth.…”

Section: Discussionmentioning

confidence: 83%

Zoledronic Acid as a New Adjuvant Therapeutic Strategy for Ewing's Sarcoma Patients

Odri

Dumoucel²,

Picarda³

et al. 2010

Cancer Research

View full text Add to dashboard Cite

Ewing's sarcoma (ES) is the second most frequent pediatric bone tumor also arising in soft tissues (15% of cases). The prognosis of patients with clinically detectable metastases at diagnosis, not responding to therapy or with disease relapse, is still very poor. Among new therapeutic approaches, bisphosphonates represent promising adjuvant molecules to chemotherapy to limit the osteolytic component of bone tumors and to protect from bone metastases. The combined effects of zoledronic acid and mafosfamide were investigated on cell proliferation, viability, apoptosis, and cell cycle distribution of human ES cell lines differing in their p53 and p16/ink4 status. ES models were developed to reproduce both soft tissue and intraosseous tumor development. Mice were treated with 100 μg/kg zoledronic acid (two or four times per week) and/or ifosfamide (30 mg/kg, one to three cycles of three injections). ES cell lines showed different sensitivities to zoledronic acid and mafosfamide at the cell proliferation level, with no correlation with their molecular status. Both drugs induced cell cycle arrest, but in the S or G 2 M phase, respectively. In vivo, zoledronic acid had no effect on soft tissue tumor progression, although it dramatically inhibited ES development in bone. When combined with ifosfamide, zoledronic acid exerted synergistic effects in the soft tissue model: Its combination with one cycle of ifosfamide resulted in an inhibitory effect similar to three cycles of ifosfamide alone. This very promising result could allow clinicians to diminish the doses of chemotherapy.

show abstract

Section: Discussionmentioning

confidence: 83%

Zoledronic Acid as a New Adjuvant Therapeutic Strategy for Ewing's Sarcoma Patients

Odri

Dumoucel²,

Picarda³

et al. 2010

Cancer Research

View full text Add to dashboard Cite

show abstract

“…Kijima et al also reported that bone metastasis of renal cell carcinoma was reossified by radiotherapy combined by ZA. 5 Their case report suggested that ZA might have effect on reossification of osteolytic metastatic lesions in combination with treatments for bone metastasis, such as radiotherapy. Although we cannot verify the adoptive effect of zoledronic acid on the reossification, this combination may be an effective treatment for bone metastases of CDC.…”

Section: Discussionmentioning

confidence: 99%

A Case of Metastatic Collecting Duct Carcinoma Whose Massive Skull Bone Metastasis was Prominently Reossified by Gemcitabine Plus Cisplatin Chemotherapy Combined with Zoledronic Acid

Kikuchi

Ito

Shimazaki

et al. 2017

Urology Case Reports

View full text Add to dashboard Cite

The present case underwent right laparoscopic radical nephrectomy for collecting duct carcinoma (CDC). Recurrence occurred in the lung and the bone (skull and lumber vertebra) in 2011. Gemcitabine plus cisplatin (GC) chemotherapy and monthly zoledronic acid (ZA) was then started. The massive skull bone metastases were prominently reossified after several courses of the therapy. The patient received 16 courses of GC chemotherapy and monthly ZA, and pulmonary metastases and reossified skull bone metastases were stable for 23 months. Although we cannot verify the adoptive effect of ZA on the reossification, this combination may be effective for CDC bone metastases.

show abstract

“…This was also associated with sustained PFS (more than 20 months [88]. Other BP treatments of RCC patients could also result in an improvement in metastatic disease involving bone and lungs [89].…”

Section: Tyrosine Kinase Inhibitors and Bone Metastases Of Renal Cellmentioning

confidence: 97%

Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone

et al. 2013

View full text Add to dashboard Cite

Skeletal involvement is common in patients with renal cell carcinoma (RCC): ∼30% of patients with metastatic RCC (mRCC) will develop bone metastases. Inhibition of vascular endothelial growth factor (VEGF) has been pursued as a therapeutic target in the treatment of metastatic clear-cell RCC (m-ccRCC). Tyrosine kinase inhibitors (TKIs), such as sunitinib, pazopanib, sorafenib, and the monoclonal antibody bevacizumab, became the therapy of choice for patients with m-ccRCC. Besides the undisputed efficacy of TKI in the treatment of m-ccRCC, the problem of metastatic bone disease still remains. There is evidence that the presence of bone metastases in m-ccRCC patients has a significant and clinically relevant negative impact on survival and potentially on the outcome of VEGF-targeted therapy. Also, a relatively common practice in the treatment of such patients is bone-directed therapy with bisphosphonates (BPs). Recent evidence shows a potentially synergistic effect on efficacy but also the potential for increased toxicity of combining TKIs and BPs. This review article highlights the importance of this subject and aims to facilitate further research and optimize the treatment of this important and common group of RCC patients.

show abstract

Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: A case report

Cited by 8 publications

References 9 publications

Zoledronic Acid as a New Adjuvant Therapeutic Strategy for Ewing's Sarcoma Patients

Zoledronic Acid as a New Adjuvant Therapeutic Strategy for Ewing's Sarcoma Patients

A Case of Metastatic Collecting Duct Carcinoma Whose Massive Skull Bone Metastasis was Prominently Reossified by Gemcitabine Plus Cisplatin Chemotherapy Combined with Zoledronic Acid

Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone

Contact Info

Product

Resources

About